Tenofit E Tablet contains Emtricitabine 200mg, Tenofovir Disoproxil Fumarate 300mg, and Efavirenz 600mg, a globally accepted fixed-dose antiretroviral therapy used as a first-line regimen for the management of HIV-1 infection. This triple-drug combination works synergistically to suppress viral replication and reduce HIV viral load effectively.
The formulation combines two nucleoside reverse transcriptase inhibitors with a non-nucleoside reverse transcriptase inhibitor, providing potent antiviral activity with once-daily dosing convenience. Its proven efficacy and long-term safety profile make it a cornerstone therapy in national and international HIV treatment guidelines.
For hospitals, ART centers, and institutional healthcare providers, Tenofit E Tablet is a consistently required antiretroviral medicine, widely used in government HIV programs, private infectious disease clinics, and specialty hospitals. Long-term treatment protocols ensure continuous demand and repeat procurement.
Adding Tenofit E Tablet to your product range strengthens your HIV and antiretroviral therapy segment, opening opportunities in hospital supply chains, public health tenders, export markets, and third-party manufacturing. Its essential role in HIV management makes it a clinically significant and commercially valuable product for pharmaceutical distributors.